Slide 1: Elan plc
Elan ple May 16", 2011 élan
Slide 2: Safe Harbor Statement
This presentation contains forward-looking statements about Elan's financial condition, results of operations and business prospects that involve substantial risks and uncertainties. A list and description of these risks, uncertainties and other matters can be found in Elan's Annual Report on Form 2
Slide 3: Safe Harbor Statement (continued)
This document includes forward-looking statements as defined by the SEC. All statements, other than statements of historical fact, included herein that address activities, events or developments that Elan, EDT, New Alkermes or Alkermes, Inc. expects, believes or anticipates will or may occur in the
Slide 4: Transaction Details
Transaction Details Elan has entered into a business combination and merger agreement with Alkermes, Inc to combine EDT with Alkermes, Inc, creating a new Irish public company ("New Alkermes") Elan to receive $500m cash plus 31.9m shares in New Alkermes upon closing Total value approximately $960 mi
Slide 5: New Alkermes
New Alkermes Diversified, profitable biopharmaceutical company Commercial presence and revenues from five major commercial products Risperdal(r) Consta(r), Invega(r) Sustenna(r), Ampyra(r), Vivitrol(r) & Bydureon(tm) (not yet approved, positive opinion from CHMP) Two of the most important long-actin
Slide 6: Elan plc: Balance Sheet Impact
Elan plc: Balance Sheet Impact (CHART) * PF investments assume 31.9m shares in Alkermes plc at $14.47 each. Excludes equity method investment in JAI. Investments Cash Cash Down 1/3 Up ~2x Debt Cash & Investments* (CHART) Interest Expense Down 1/3
Slide 7: Elan plc: 2012 and Beyond
Elan plc: 2012 and Beyond Science Parkinson's Disease Genetics Neotope Invest in strategic IP Tysabri* Accelerate market share Broaden commercial availability of assay Establish personalised risk stratification Invest in life cycle opportunities Pipeline Advance current programs D005, D002, D007 Sel
Slide 8: Elan plc: Tysabri Patient Stratification Allows For Significant Growth
Elan plc: Tysabri Patient Stratification Allows For Significant Growth Significant clinical, regulatory and commercial progress with Stratify JCV assay in US and Europe CE marking of assay in Europe and currently available CHMP adopted a positive opinion for inclusion of an additional risk factor, a
Slide 9: Elan plc: 2012 and Beyond
Elan plc: 2012 and Beyond Science based, high growth, biotechnology company Leading MS Therapeutic business Distinctive approach to discovery science targeted towards a broad array of neurology Headcount of ~450 Headquartered in Dublin, Discovery / Science / Development in San Francisco Net cash & i
Slide 10: Upcoming Key Events
Upcoming Key Events Tysabri US commercial availability of JCV assay in mid-2011 EU label update for JCV antibody status in mid-2011 US label update for JCV antibody status in H2 2011 Selective investments in opportunities within neurology Bapineuzumab* Phase III US data mid 2012 Notes: *Development
Slide 11: Appendices
Appendices
Slide 12: 2008 to 2010 - BioNeurology and EDT
2008 to 2010 - BioNeurology and EDT
Slide 13: Q1 2011 - BioNeurology and EDT
Q1 2011 - BioNeurology and EDT
Slide 14: BioNeurology Stand-Alone
13 13 BioNeurology Stand-Alone Revenue Adjusted EBITDA Operating Expenses *Operating Profit (CHART) (CHART) (CHART) (CHART) R&D SG&A ($ Millions) ($ Millions) ($ Millions) ($ Millions) *Pre-charges
Slide 15: Tysabri Black Box Warning
Tysabri Black Box Warning TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability. Cases of PML have been reported in patients taking TYSABRI who were recently or concomitantly trea
Slide 16: Elan
élan